Class 4 Medicines Defect Information: Galderma (U.K.) Limited, epiduo gel pump 0.1% 45g

Galderma (U.K.) Limited has informed the MHRA that the Patient Information Leaflet (PIL) packaged in some batches of Epiduo 0.1% / 2.5% gel contain outdated safety information regarding pregnancy.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-galderma-uk-limited-epiduo-0-dot-1-percent-slash-2-dot-5-percent-gel-45-g-el-22-a-slash-52

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For more information, medical information queries or replacement PIL enquiries, please contact: medinfo.uk@galderma.com

For stock control queries, please contact: sales.uk@galderma.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Class 4 Medicines Defect Information: Galderma (U.K.) Limited, Etrivex 500 micrograms/g Shampoo

Galderma (U.K.) Limited has informed the MHRA that the patient information leaflet (PIL) packaged in specific batches of Etrivex Shampoo is missing safety information

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-galderma-uk-limited-etrivex-500-micrograms-slash-g-shampoo-el-22-a-slash-51?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=90e00faf-8782-4c58-b00a-5c6c196d3cb8&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For more information, medical information queries or replacement PIL enquiries, please contact: medinfo.uk@galderma.com

For stock control queries, please contact: sales.uk@galderma.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Class 4 Medicines Defect Information: ADVANZ Pharma Ltd, MacroBID 100mg Prolonged-Release Capsules

ADVANZ PHARMA has made the MHRA aware that certain batches of MacroBID 100mg Prolonged-Release Capsules have been packed with the incorrect Patient Information Leaflet (PIL).

MHRA drug alert date: 5th December 2022

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-advanz-pharma-macrobid-100mg-prolonged-release-capsules-el-22-a-slash-50?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=7dca1a8e-a797-4234-b6cb-7c92576fc0d0&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For further information, medical enquiries, stock information or request for printed copy of the associated SmPC, please contact telephone: + 44 (0) 208 5889 131 or via email: medicalinformation@advanzpharma.com.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Skills in Healthcare and HRA Pharma UK win Best OTC Pharmacy Training and Learning Award

On Monday 28 November, at the OTC Marketing Awards in London, Alliance Healthcare enjoyed an evening of celebration. Our Skills in Healthcare Team, alongside our client HRA Pharma UK won the Best OTC Pharmacy Training and Learning Award for their product, Hana.

Paul Fowler, Head of Skills in Healthcare said: “I’m so proud of our Pharmacy training team and their win yesterday evening. It’s fantastic recognition of the great work they all do to support the success of our manufacturer client’s brands in pharmacy, and of the support they provide to instore teams within our retail pharmacy partners by delivering high quality, face to face, in pharmacy training that supports customer care excellence and expert recommendation. Congratulations to everyone involved!“

Hinckley service update 2 December

We are pleased to share normal service has resumed at our Hinckley Service Centre. We thank you for your understanding whilst our teams worked at speed to ensure service stability during this time.  

Hinckley Service Update 1 December

We are now operating a normal delivery service from our Hinckley Service Centre. However, to ensure continued stability of service, we need to make a temporary change to this evening’s order cut off time to 6pm. Please try to transmit orders before this time. We are sorry for any inconvenience this causes you or your patients and thank you in advance for your understanding.

Hinckley service update 30 November 

We have experienced an exceptional increase in order volume at our Hinckley Service Centre which has impacted our ability to process some orders. Despite robust planning to ensure service consistency throughout the peak season (where an uplift in volume is always anticipated), our Hinckley site experienced an unprecedented increase overnight. 

You may be missing some items in your deliveries this afternoon. For assurance, all fridge and controlled drug items are unaffected and will arrive with you as normal. Any items you do not receive this afternoon will be with you tomorrow morning – you do not need to re-order.

Please contact Customer Service for any emergency requirements.

In order to support our recovery, we need to make a temporary change to this evening's order cut off time to 5pm. Please try to transmit orders before this time. We are sorry for any inconvenience this causes you or your patients and thank you in advance for your understanding. 

Class 4 Medicines Defect Information: Lucis Pharma Ltd, Oxycodone Hydrochloride 10mg/ml oral solution

Lucis Pharma Ltd has informed the MHRA that there is a typographical error with text on the rear side of the outer packaging for Oxycodone Hydrochloride 10mg/ml Oral Solution.

MHRA drug alert date: 29 November 2022

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-lucis-pharma-ltd-oxycodone-hydrochloride-10mg-slash-ml-oral-solution-el-22-a-slash-49?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1864253f-7b0a-4b30-9aad-78ec2edb6c19&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For medical information and stock control queries please contact: enquiries@lucispharma.co.uk.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Christmas and New Year Bank Holiday Opening Hours 2022

To help keep our customers informed of changes to our service, we have published our bank holiday opening hours for the 2022 Christmas and New Year period.

View our bank holiday opening hours:

For Pharmacy/Retail – Christmas and New Year Bank Holiday Opening Hours 2022

For Hospitals – Christmas and New Year Bank Holiday Opening Hours 2022

CLASS 4 CAUTION IN USE - HYOSCINE BUTYLBROMIDE 20 MG FILM-COATED TABLETS

Morningside Healthcare Limited has informed the MHRA of an error with the Patient Information Leaflet (PIL) packaged in batch 22237001 of Hyoscine Butylbromide 20 mg Film-coated Tablets. Some packs within the batch may contain a PIL for Midodrine Hydrochloride 2.5 mg & 5 mg Tablets. The issue was identified due to a market complaint, which noted that a Midodrine Hydrochloride 2.5 mg & 5 mg Tablets leaflet had been found in a pack of Hyoscine Butylbromide 20 mg Film-coated Tablets, batch 22237001, expiry date 04/2025.

MHRA drug alert date: 21st November 2022

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-morningside-healthcare-limited-hyoscine-butylbromide-20-mg-film-coated-tablets-el-22-a-slash-48?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=cfd26f4f-9046-4674-9924-980b00650278&utm_content=immediately

This is a caution in use only we are not accepting stock returns.

Further Information:

For further information please contact: Morningside Healthcare Ltd, Morningside House, Unit C Harcourt Way, Meridian Business Park, Leicester, LE19 1WP,

Telephone: +44 (0)116 2045950

For medical information enquiries, please contact: medicalenquiry@morningsidehealthcare.com or Telephone +44 (0)116 478 0322 and for all stock enquiries, please contact Telephone: +44 (0)1162045950